✦ New CED Clinical Relevance #55 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyIndustry Why This Matters West Virginia’s $34 million in unspent medical cannabis program revenue represents...
Cannabis Compounds Exhibit Potential in Combatting Fatty Liver Disease
✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchCBDTHCAging Why This Matters Clinicians managing patients with fatty liver disease now have preliminary evidence...
Study reveals cannabis compounds reduce threat of fatty liver disease | Health – CBS19
✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. ResearchCBDTHCHemp Why This Matters This finding is clinically relevant because non-alcoholic fatty liver disease affects...
Daily Digest: Last 6 Hours: Cognitive Safety, Liver Disease Breakthroughs, and the Drug Testing Problem That Won’t Go Away — March 06, 2026
A synthesis of 20 recently added cannabis articles — key themes, clinical context, and Dr. Caplan’s take.
Regulatory Digest 2026-03-06
✦ New Regulatory updates (higher clinical relevance) (100) [regulations.gov] Schedules of Controlled Substances: Rescheduling of Marijuana (85) [regulations.gov] Bulk Manufacturer-Royal Emerald (2024-11786) DEA1368 (85) [regulations.gov] Exempt Chemical Preparations May 2024 (2024-10465) –...
Daily Digest 2026-03-06
✦ New Top items from the CED news pipeline. (82) Scientists are raising new concerns about marijuana use in teens – KPBSResearch continues to build a concerning picture around adolescent cannabis use...
Daily Digest: Last 48 Hours: Cognitive Safety, End-of-Life Access, and the Impairment Testing Problem — March 06, 2026
A synthesis of 102 recently added cannabis articles — key themes, clinical context, and Dr. Caplan’s take.
SA risks missing R40bn hemp industry opportunity without coherent strategy – Business Day
WHY IT MATTERS: Patients in South Africa relying on locally sourced CBD products could face ongoing supply inconsistencies and price volatility if the hemp sector remains without a clear regulatory and agricultural framework. CLINICAL OVERVIEW: South Africa sits on a significant economic and agricultural opportunity with hemp, a crop that can generate billions in revenue while also supplying raw materials for CBD-based health products and industrial applications. Without a coordinated national strategy that aligns regulatory frameworks, agricultural policy, and research infrastructure, the country risks ceding that market position to competitors who have already established coherent legal pathways.
Veterans Groups Urge Congress To Expand Psychedelics And Marijuana Access To …
WHY IT MATTERS: Veterans currently using cannabis or pursuing psychedelic therapy outside the VA system risk losing continuity of care, benefits eligibility concerns, and lack of clinical supervision that a formal federal program would provide. CLINICAL OVERVIEW: Veterans organizations are pressing Congress to broaden access to both cannabis and psychedelic-assisted therapies through the VA system as a response to the persistently high suicide rate among veterans. The push reflects growing clinical evidence that current pharmacological and psychological treatment options are failing a significant portion of this population, particularly those with treatment-resistant PTSD and co-occurring substance use disorders.
Brazil’s Cannabis Crossroads: New Rules, Old Truths, and the Road Ahead
WHY IT MATTERS: Patients in Brazil and those watching international cannabis policy should know that new domestic cultivation rules could meaningfully expand access to locally produced, regulated cannabis medicines, potentially lowering costs and improving product consistency. CLINICAL OVERVIEW: Brazil’s updated cannabis regulatory framework represents a significant shift toward integrating medical cannabis into the formal healthcare system, including provisions for domestic cultivation under health authority oversight. The framework addresses THC-containing products more explicitly, which has direct implications for how physicians can recommend and patients can access a broader range of cannabinoid formulations.